Surge in Drug-Resistant Bacteria Infections Raises Alarm in the U.S.
A recent report from the Centers for Disease Control and Prevention (CDC) highlights a troubling rise in infections caused by drug-resistant bacteria across the United States. The CDC has observed a significant increase in a particular strain known as NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE).
These bacteria belong to a broader group called carbapenem-resistant Enterobacterales (CRE), which are known for their ability to withstand some of the strongest antibiotics available. The term “NDM” refers to an enzyme that makes these bacteria resistant to nearly all antibiotics.
In 2020 alone, NDM-CRE was linked to around 12,700 infections and about 1,100 fatalities in the U.S. The CDC warns that the recent spike may push these figures even higher.
Infections caused by NDM-CRE can manifest in various forms, including urinary tract infections, pneumonia, bloodstream infections, and wound infections. Alarmingly, there has been more than a 460% increase in these infections between 2019 and 2023. Because they are resistant to many antibiotics, these infections can be challenging to treat and could lead to severe health problems or even death. Moreover, they can spread quickly within communities.
Experts also point out that NDM-CRE infections can often be misdiagnosed or overlooked. This is a concern because the bacteria are relatively new in the U.S. and may not be on the radar of healthcare providers.
Danielle Rankin, an epidemiologist at the CDC, emphasized the seriousness of this situation: “This sharp rise in NDM-CRE means we face a growing threat, making it harder to treat severe bacterial infections.” She urged healthcare providers to ensure they have access to proper testing to help guide treatment decisions.
Dr. Marc Siegel, a senior medical analyst, expressed worry over this trend, describing it as a “very concerning” issue with a high risk of severe illness or death. He noted that part of the problem stems from the overuse of antibiotics and a global increase in resistance.
To combat these difficult infections, doctors may use newer antibiotics such as ceftazidime-avibactam and meropenem-vaborbactam. However, Dr. Siegel pointed out that the market does not incentivize the creation of new antibiotics, leaving healthcare providers with limited options.
Dr. David Perlin, an expert in infectious diseases, underscored the gravity of the situation, noting that these bacteria constantly adapt, creating new resistance mechanisms that complicate treatment efforts.
Perlin stressed the importance of quickly identifying these infections for effective treatment. He believes that healthcare providers need to improve their testing practices, especially in emergency departments, to curb the spread and impact of these infections.
The rise of NDM-CRE poses a significant threat to public health, particularly for those with weakened immune systems. It is crucial for patients to advocate for their health and communicate any ongoing infections to their doctors.
In light of this situation, both experts encourage more rigorous testing and rapid response in order to better manage and treat these dangerous bacterial infections effectively.
